Clinical Drug Experience Knowledgebase

imatinib (gleevec) (6 trials)

nilotinib (tasigna) (5 trials)

aldesleukin (Proleukin) (1 trial)

allogeneic hematopoietic stem cells (Hemacord) (2 trials)

amsacrine (1 trial)

arsenic trioxide (trisenox) (2 trials)

autologous hematopoietic stem cells (3 trials)

azacitidine (vidaza) (3 trials)

bleomycin (blenoxane) (1 trial)

blinatumomab (blincyto) (3 trials)

bone autograft (2 trials)

bortezomib (velcade) (3 trials)

busulfan (Myleran) (2 trials)

carmustine (bicnu) (1 trial)

cyclophosphamide (cytoxan) (8 trials)

cytarabine (cytosar-u) (11 trials)

dacarbazine (dtic-dome) (1 trial)

daunorubicin (cerubidine) (9 trials)

decitabine (dacogen) (2 trials)

deferasirox (exjade) (1 trial)

doxorubicin (Doxil) (2 trials)

etoposide (vepesid) (8 trials)

fludeoxyglucose f-18 (1 trial)

gemtuzumab ozogamicin (mylotarg) (3 trials)

glasdegib (Daurismo) (1 trial)

ibrutinib (imbruvica) (4 trials)

idarubicin (idamycin) (10 trials)

lenalidomide (revlimid) (4 trials)

melphalan (alkeran) (1 trial)

mercaptopurine (purinethol) (6 trials)

midostaurin (rydapt) (1 trial)

mitoxantrone (novantrone) (6 trials)

naltrexone (revia) (6 trials)

obinutuzumab (gazyva) (2 trials)

ponatinib (iclusig) (5 trials)

prednisone (meticorten) (5 trials)

procarbazine (matulane) (1 trial)

sargramostim (leukine) (3 trials)

tioguanine (Lanvis) (2 trials)

tretinoin (Retin-A) (6 trials)

urea (5 trials)

venetoclax (venclexta) (6 trials)

vinblastine (velban) (1 trial)

vincristine (oncovin) (5 trials)

alemtuzumab (campath) (1 trial)

allogeneic stem cells (1 trial)

asparaginase (elspar) (4 trials)

bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine (1 trial)

bendamustine (treanda) (1 trial)

bosutinib (bosulif) (1 trial)

chlorambucil (Leukeran) (1 trial)

clofarabine (clolar) (3 trials)

dasatinib (sprycel) (2 trials)

eltrombopag (promacta) (2 trials)

fludarabine (fludara) (3 trials)

inotuzumab ozogamicin (besponsa) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

methylprednisolone (medrol) (2 trials)

ofatumumab (arzerra) (3 trials)

rituximab (rituxan) (3 trials)

tagraxofusp-erzs (elzonris) (1 trial)

temsirolimus (torisel) (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

valproic acid (depakene) (1 trial)

autologous natural killer cells (1 trial)

everolimus (zortress) (1 trial)

adrenomedullin (22-52) (1 trial)

autologous bone marrow derived mesenchymal cells (1 trial)

COVID-19 convalescent plasma (1 trial)

ifosfamide (ifex) (1 trial)